In type 2 diabetic patients treated with insulin and SGLT2i, glycemic control may be determined by an improvement of insulin resistance due to body weight loss, an improvement of glucotoxicity by insulin and/or SGLT2i, administered insulin dose, and RTG reduced because of SGLT2i [17]. The gene discussed is INS; the disease is Insulin resistance.